Key facts
- · What it is: Annual report · C-AR
- · What it is: Progress update · C-U
- · Intermediary: StartEngine Primary, LLC · Target: $20K · Maximum: $1.23M · Deadline: 2025-04-30 · Security: Series Seed-2 Preferred Stock · C/A
- · What it is: Progress update · C-U
- · Intermediary: StartEngine Primary, LLC · Target: $124K · Maximum: $1.23M · Deadline: 2025-03-12 · Security: Series Seed-2 Preferred Stock · C
Diant Pharma Inc., based in Manchester, CT, filed 2 Regulation Crowdfunding offering filings with the SEC, the latest on 2025-03-12, raising through StartEngine Primary, LLC. It set a target of $20K and will accept up to $1.23M. The security offered is series seed-2 preferred stock at $1.88 each. As of its filings the offering is past its deadline of 2025-04-30. 5 filings in this family are on record for the company.
Offering filings
| Filed | Intermediary | Target | Maximum | Deadline | Security | Filing |
|---|---|---|---|---|---|---|
| 2025-03-12 | StartEngine Primary, LLC | $20K | $1.23M | 2025-04-30 | Series Seed-2 Preferred Stock | C/A |
| 2024-12-11 | StartEngine Primary, LLC | $124K | $1.23M | 2025-03-12 | Series Seed-2 Preferred Stock | C |
Want the whole picture on Diant Pharma Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Diant Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Diant Pharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Financials the company filed
Figures from the C-AR filed 2026-05-08, as the company reported them.
| As filed | Most recent fiscal year | Prior fiscal year |
|---|---|---|
| Revenue | $1.53M | $849K |
| Net income | -$538K | -$414K |
| Total assets | $1.69M | $1.77M |
| Cash and equivalents | $29K | |
| Short-term debt | $265K | |
| Long-term debt | $190K |
Employees at filing: 9.
Progress updates
2025-05-08, C-U:
At the close of the offering, the issuer closed on $0.00 and 0 number of securities.
2024-12-26, C-U:
The issuer has raised over 100% ($140,643.38) of the offering target amount ($123,999.16).
People who signed the filing
- Antonio Costa, CEO
- Bryan J. Kotlarz, CFO
Every filing
| Filed | What it is | Filing |
|---|---|---|
| 2026-05-08 | Annual report | C-AR |
| 2025-05-08 | Progress update | C-U |
| 2025-03-12 | Offering amended | C/A |
| 2024-12-26 | Progress update | C-U |
| 2024-12-11 | Offering | C |
A crowdfunding round is won in public. FoxPlug turns your commits, deploys and releases into the posts and visuals that keep the story moving while the offering is open.
Build your launch kitRun a Snapshot on Antonio Costa: other companies, roles and the record behind them. Order Full Report from there if you need more.
Snapshot the foundersTools for this story
Each opens in a new tab, filled in for Diant Pharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company raising money from the public under Regulation Crowdfunding has to file with the SEC before the offering opens, and has to raise through a single registered intermediary: a funding portal or a broker-dealer. The first filing, Form C, states how much the company is trying to raise, the most it will accept, the deadline, the security and its price, the intermediary and what the intermediary is paid, and two years of the company's own financial figures.
After that the company files amendments when terms change, progress updates as the raise moves, and an annual report each year until it stops reporting. Every row here is one of those filings, linked to the filing itself, so each figure can be checked at the source. Figures are exactly as the company filed them; where a filing leaves a field blank, so does this page. Nothing here is investment advice, and a filing is the company's own statement, not a verification of it.